Showing 2241-2250 of 5696 results for "".
- Ciliatech Releases New Design of Glaucoma Surgical Device CIDhttps://modernod.com/news/ciliatech-releases-new-design-of-glaucoma-surgical-device-cid/2481993/Ciliatech announced the release of a new design of its CID (cilioscleral interpositioning device) following the filing of additional patents strengthening its IP (intellectual property). CID is the unique glaucoma surgical device used in the cilioscleral technique to lower IOP whil
- Signs of Glaucoma May Be Detectable Years in Advance of Disease Onsethttps://modernod.com/news/nih-signs-of-glaucoma-may-be-detectable-years-in-advance-of-disease-onset/2481989/Research funded by the National Eye Institute suggests that low density of pigment in the macula, the region of the retina required for sharp central vision, is associated with thinning of the retina and may serve as an early warning sign of glaucoma. The findings are based on nearly 400 women wh
- Genentech and Nvidia Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Developmenthttps://modernod.com/news/genentech-and-nvidia-enter-into-strategic-ai-research-collaboration-to-accelerate-drug-discovery-and-development/2481979/In a move aimed at speeding up drug discovery and development, Genentech announced a multi-year strategic research collaboration with Nvidia. Financial terms of the deal were not disclosed. The partnership will combine Genentech’s artificial intelligence
- EyeBio Announces Expansion of Series A to $130 Million to Advance Development of Restoret for Retinal Diseaseshttps://modernod.com/news/eyebio-announces-expansion-of-series-a-to-130-million-to-advance-development-of-restoret-for-retinal-diseases/2481969/Eyebiotech announced the successful close of an extension to its Series A financing, bringing the total raised to date to $130 million. EyeBio will use the proceeds from the funding to accelerate the company’s clinical development program and further build out its retina pipeline.
- Ocutrx Unveils OcuLenz AR/XR Headset, Aiding Vision for Patients with Advanced Macular Degenerationhttps://modernod.com/news/ocutrx-unveils-oculenz-arxr-headset-aiding-vision-for-patients-with-advanced-macular-degeneration/2481968/Ocutrx Technologies has released the OcuLenz AR/XR headset, which is designed to enhance visual clarity for people living with advanced age-related macular degeneration (AMD). The AR/XR headset enhances vision by overlaying high-contrast, pixel-manipulated images onto the user
- Atsena Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Gene Therapy for LCA1https://modernod.com/news/atsena-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-gene-therapy-for-lca1/2481966/Atsena Therapeutics announced the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ATSN-101, the company’s lead investigational gene therapy for patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). RMAT desi
- Lumenis’ OptiPlus Dual-Frequency RF Energy Device Launchedhttps://modernod.com/news/lumenis-optiplus-dual-frequency-rf-energy-device-launched/2481949/Lumenis announced the launch of the OptiPlus dual-frequency radiofrequency (RF) device, which is designed to deliver heat across different tissue layers, thus increasing blood circulation to promote medical performance and aesthetic results. According to the company, OptiPlus is a
- Kodiak Reboots Tarcocimab Tedromer Development Program Following Strong Positive Phase 3 DR Resultshttps://modernod.com/news/kodiak-reboots-tarcocimab-tedromer-development-program-following-strong-positive-phase-3-diabetic-retinopathy-results/2481948/Three months after deciding to discontinue tarcocimab tedromer due to two failed late-stage trials, Kodiak Sciences announced it is rebooting its clinical program after its phase 3 GLOW superiority study evaluating tarcocimab tedromer 5 mg in moderately severe to sev
- GALE Extension Study Shows Syfovre Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with GAhttps://modernod.com/news/gale-extension-study-shows-syfovre-continued-to-demonstrate-increasing-treatment-effects-over-3-years-in-patients-with-ga/2481943/Apellis Pharmaceuticals announced data from the GALE extension study following 3 years of continuous treatment with Syfovre (pegcetacoplan injection), the first FDA-approved treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The data were rep
- Pantheon Vision Raises $2.5 Million in Seed Funding to Launch Development of Bioengineered Corneal Implanthttps://modernod.com/news/pantheon-vision-raises-25-million-in-seed-funding-to-launch-development-of-bioengineered-corneal-implant/2481936/Pantheon Vision has announced $2.5 million in seed financing from Baltimore-based KeraLink International (KLI), a non-profit organization singularly focused on eradicating corneal blindness with an emphasis on low- and middle-income countries. The funding will be us